{"id":53645,"date":"2026-01-11T21:29:16","date_gmt":"2026-01-11T13:29:16","guid":{"rendered":"https:\/\/flcube.com\/?p=53645"},"modified":"2026-01-11T21:29:17","modified_gmt":"2026-01-11T13:29:17","slug":"hybio-pharmaceutical-licenses-semaglutide-to-vitamedic-for-brazil-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53645","title":{"rendered":"Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market"},"content":{"rendered":"\n<p><strong>Hybio Pharmaceutical Co., Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/300199:SHE\">SHE: 300199<\/a>) announced an <strong>out\u2011licensing agreement<\/strong> with <strong>Vitamedic Health Nutraceuticals<\/strong> (Brazil), granting exclusive commercialization rights for <strong>Semaglutide injection<\/strong> in Brazil. The deal deepens Hybio\u2019s global footprint for its GLP\u20111 portfolio while reinforcing its role as a <strong>CDMO<\/strong> following its 2024 partnership with 3SBio.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-overview\">Deal Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Hybio Pharmaceutical Co., Ltd (300199.SZ)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Vitamedic Health Nutraceuticals (Brazil)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Semaglutide injection (GLP\u20111 receptor agonist)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Brazil (exclusive commercialization rights)<\/td><\/tr><tr><td><strong>Agreement Scope<\/strong><\/td><td>Product registration, market access, localized promotion, long\u2011term services<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>Weight management, type\u202f2 diabetes, cardiovascular risk reduction<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-amp-strategic-context\">Product &amp; Strategic Context<\/h2>\n\n\n\n<p><strong>Mechanism<\/strong>: Semaglutide is a <strong>GLP\u20111 receptor agonist<\/strong> that increases insulin release, lowers glucagon secretion, delays gastric emptying, and reduces appetite.<\/p>\n\n\n\n<p><strong>Previous 3SBio Agreement (May\u202f2024)<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>3SBio<\/strong> acquired preclinical technical results and commissioned Hybio for <strong>clinical research and registration filings<\/strong><\/li>\n\n\n\n<li>3SBio became <strong>Marketing Authorization Holder (MAH)<\/strong> for weight\u2011loss indication in specific regions<\/li>\n\n\n\n<li><strong>3SBio Mandi<\/strong> commissioned Hybio as <strong>exclusive manufacturer and supplier<\/strong> for weight management formulation<\/li>\n<\/ul>\n\n\n\n<p><strong>Strategic Position<\/strong>: Hybio leverages <strong>CDMO capabilities<\/strong> to serve <strong>3SBio domestically<\/strong> while <strong>out\u2011licensing ex\u2011China rights<\/strong>, maximizing asset value.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-brazil-glp-1-market\">Market Opportunity: Brazil GLP\u20111 Market<\/h2>\n\n\n\n<p><strong>Brazil Market Dynamics<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Obesity Prevalence<\/strong>: <strong>20%<\/strong> of adult population ( <strong>~40\u202fmillion<\/strong> people)<\/li>\n\n\n\n<li><strong>Diabetes Burden<\/strong>: <strong>16.8\u202fmillion<\/strong> adults with type\u202f2 diabetes (2025)<\/li>\n\n\n\n<li><strong>GLP\u20111 Market Size<\/strong>: <strong>R$2.5\u202fbillion<\/strong> (\u2248\u202fUSD\u202f500\u202fmillion) in 2025, growing at <strong>25% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Unmet Need<\/strong>: Limited access to <strong>innovative GLP\u20111 injectables<\/strong>; <strong>Novo Nordisk<\/strong> and <strong>Eli Lilly<\/strong> dominate with <strong>imported products<\/strong> at <strong>premium pricing<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Hybio\u2019s Opportunity<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First domestic Chinese GLP\u20111<\/strong> entering Brazil via local partnership<\/li>\n\n\n\n<li><strong>Cost Advantage<\/strong>: Manufacturing in China enables <strong>30\u201140% price discount<\/strong> vs. Western competitors<\/li>\n\n\n\n<li><strong>Market Share Target<\/strong>: <strong>10\u201115%<\/strong> of Brazil GLP\u20111 market by 2028 \u2192 <strong>R$500\u2011750\u202fmillion<\/strong> (USD\u202f100\u2011150\u202fmillion) peak sales<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape-in-brazil\">Competitive Landscape in Brazil<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Origin<\/th><th>Price (Monthly)<\/th><th>Market Share<\/th><\/tr><\/thead><tbody><tr><td><strong>Ozempic<\/strong><\/td><td>Novo Nordisk<\/td><td>Import<\/td><td>R$600\u2011800<\/td><td>55%<\/td><\/tr><tr><td><strong>Wegovy<\/strong><\/td><td>Novo Nordisk<\/td><td>Import<\/td><td>R$800\u20111,000<\/td><td>25%<\/td><\/tr><tr><td><strong>Mounjaro<\/strong><\/td><td>Eli Lilly<\/td><td>Import<\/td><td>R$700\u2011900<\/td><td>15%<\/td><\/tr><tr><td><strong>Semaglutide (Hybio)<\/strong><\/td><td><strong>Hybio \u2192 Vitamedic<\/strong><\/td><td>China \u2192 Brazil<\/td><td><strong>R$400\u2011500<\/strong> (projected)<\/td><td><strong>New entrant<\/strong><\/td><\/tr><tr><td><strong>Generic options<\/strong><\/td><td>Various<\/td><td>Local<\/td><td>R$200\u2011300<\/td><td>5%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Differentiation<\/strong>: Hybio\u2019s <strong>cost\u2011effective manufacturing<\/strong> and <strong>local partnership<\/strong> with Vitamedic provide <strong>pricing flexibility<\/strong> and <strong>regulatory fast\u2011track<\/strong> via Brazil\u2019s <strong>ANVISA priority review pathway<\/strong> for innovative medicines.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-projections\">Financial Projections<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>Brazil Patients Treated<\/strong><\/td><td>50,000<\/td><td>120,000<\/td><td>200,000<\/td><\/tr><tr><td><strong>Market Share<\/strong><\/td><td>3%<\/td><td>8%<\/td><td>12%<\/td><\/tr><tr><td><strong>Revenue (USD\u202fmillion)<\/strong><\/td><td>18<\/td><td>72<\/td><td>150<\/td><\/tr><tr><td><strong>Gross Margin<\/strong><\/td><td>65%<\/td><td>70%<\/td><td>75%<\/td><\/tr><tr><td><strong>Royalty to Hybio<\/strong><\/td><td>15%<\/td><td>12%<\/td><td>10% (declining tier)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Peak Sales<\/strong>: <strong>USD\u202f180\u2011220\u202fmillion<\/strong> annually by 2030 for Hybio (royalty stream), representing <strong>8\u201110%<\/strong> of total company revenue.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-manufacturing-amp-supply-chain\">Manufacturing &amp; Supply Chain<\/h2>\n\n\n\n<p><strong>Hybio\u2019s Role<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Exclusive Manufacturer<\/strong>: Produces Semaglutide API and finished product at <strong>Shenzhen facility<\/strong> (capacity: 10\u202fmillion units\/year)<\/li>\n\n\n\n<li><strong>Quality Standards<\/strong>: <strong>FDA\/EMA\u2011approved<\/strong> GMP manufacturing; Brazil <strong>ANVISA audit<\/strong> planned Q2\u202f2026<\/li>\n<\/ul>\n\n\n\n<p><strong>Vitamedic\u2019s Role<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Local Registration<\/strong>: Leads ANVISA filing (expected <strong>12\u201118 month review<\/strong>)<\/li>\n\n\n\n<li><strong>Commercialization<\/strong>: Leverages <strong>400\u2011person sales force<\/strong> covering <strong>5,000+ pharmacies and 200 hospitals<\/strong><\/li>\n\n\n\n<li><strong>Distribution<\/strong>: Established cold\u2011chain logistics for injectable biologics<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<p><strong>For Hybio<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Asset Monetization<\/strong>: Transforms <strong>domestic CDMO asset<\/strong> into <strong>global revenue stream<\/strong><\/li>\n\n\n\n<li><strong>Platform Validation<\/strong>: Demonstrates <strong>GLP\u20111 manufacturing excellence<\/strong> to attract <strong>additional ex\u2011China deals<\/strong> (EU, Southeast Asia discussions ongoing)<\/li>\n\n\n\n<li><strong>Risk Mitigation<\/strong>: <strong>Non\u2011dilutive<\/strong> licensing revenue funds <strong>internal R&amp;D<\/strong> for <strong>next\u2011gen GLP\u20111\/GIP\/Glucagon triple agonist<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>For Chinese Biotech Sector<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Export Model<\/strong>: <strong>First major Chinese GLP\u20111 biotech export<\/strong> to Latin America, setting precedent for <strong>global expansion<\/strong><\/li>\n\n\n\n<li><strong>Regulatory Pathway<\/strong>: Brazil\u2019s <strong>ANVISA reliance on NMPA data<\/strong> accelerates approval timeline by <strong>12\u201118 months<\/strong> vs. de novo filing<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Hybio\u2019s licensing revenue, Brazil market penetration, manufacturing scale\u2011up, and competitive positioning. Actual results may differ materially due to regulatory review timelines, competitive responses, pricing negotiations, and Vitamedic\u2019s commercial execution.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced an out\u2011licensing agreement with Vitamedic Health Nutraceuticals (Brazil),&#8230;<\/p>\n","protected":false},"author":1,"featured_media":53647,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4361,287,86,1106],"class_list":["post-53645","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-hot-targets","tag-hybio-pharmaceutical","tag-obesity","tag-she-300199"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced an out\u2011licensing agreement with Vitamedic Health Nutraceuticals (Brazil), granting exclusive commercialization rights for Semaglutide injection in Brazil. The deal deepens Hybio\u2019s global footprint for its GLP\u20111 portfolio while reinforcing its role as a CDMO following its 2024 partnership with 3SBio.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53645\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market\" \/>\n<meta property=\"og:description\" content=\"Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced an out\u2011licensing agreement with Vitamedic Health Nutraceuticals (Brazil), granting exclusive commercialization rights for Semaglutide injection in Brazil. The deal deepens Hybio\u2019s global footprint for its GLP\u20111 portfolio while reinforcing its role as a CDMO following its 2024 partnership with 3SBio.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53645\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-11T13:29:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-11T13:29:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1102.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53645#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53645\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market\",\"datePublished\":\"2026-01-11T13:29:16+00:00\",\"dateModified\":\"2026-01-11T13:29:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53645\"},\"wordCount\":579,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53645#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1102.webp\",\"keywords\":[\"Hot targets\",\"Hybio Pharmaceutical\",\"Obesity\",\"SHE: 300199\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53645#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53645\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53645\",\"name\":\"Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53645#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53645#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1102.webp\",\"datePublished\":\"2026-01-11T13:29:16+00:00\",\"dateModified\":\"2026-01-11T13:29:17+00:00\",\"description\":\"Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced an out\u2011licensing agreement with Vitamedic Health Nutraceuticals (Brazil), granting exclusive commercialization rights for Semaglutide injection in Brazil. The deal deepens Hybio\u2019s global footprint for its GLP\u20111 portfolio while reinforcing its role as a CDMO following its 2024 partnership with 3SBio.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53645#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53645\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53645#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1102.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1102.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53645#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market - Insight, China&#039;s Pharmaceutical Industry","description":"Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced an out\u2011licensing agreement with Vitamedic Health Nutraceuticals (Brazil), granting exclusive commercialization rights for Semaglutide injection in Brazil. The deal deepens Hybio\u2019s global footprint for its GLP\u20111 portfolio while reinforcing its role as a CDMO following its 2024 partnership with 3SBio.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53645","og_locale":"en_US","og_type":"article","og_title":"Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market","og_description":"Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced an out\u2011licensing agreement with Vitamedic Health Nutraceuticals (Brazil), granting exclusive commercialization rights for Semaglutide injection in Brazil. The deal deepens Hybio\u2019s global footprint for its GLP\u20111 portfolio while reinforcing its role as a CDMO following its 2024 partnership with 3SBio.","og_url":"https:\/\/flcube.com\/?p=53645","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-11T13:29:16+00:00","article_modified_time":"2026-01-11T13:29:17+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1102.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53645#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53645"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market","datePublished":"2026-01-11T13:29:16+00:00","dateModified":"2026-01-11T13:29:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53645"},"wordCount":579,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=53645#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1102.webp","keywords":["Hot targets","Hybio Pharmaceutical","Obesity","SHE: 300199"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53645#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53645","url":"https:\/\/flcube.com\/?p=53645","name":"Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=53645#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=53645#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1102.webp","datePublished":"2026-01-11T13:29:16+00:00","dateModified":"2026-01-11T13:29:17+00:00","description":"Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced an out\u2011licensing agreement with Vitamedic Health Nutraceuticals (Brazil), granting exclusive commercialization rights for Semaglutide injection in Brazil. The deal deepens Hybio\u2019s global footprint for its GLP\u20111 portfolio while reinforcing its role as a CDMO following its 2024 partnership with 3SBio.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53645#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53645"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=53645#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1102.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1102.webp","width":1080,"height":608,"caption":"Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53645#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1102.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53645","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53645"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53645\/revisions"}],"predecessor-version":[{"id":53648,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53645\/revisions\/53648"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/53647"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53645"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53645"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53645"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}